AnalystsMatthew BieglerMatthew Biegler's Stock Forecasts
AnalystsMatthew Biegler
Sectors:
Industries:
Analyst Ranking
Bottom 10%
#4130 out of 4565 analysts
Average Return
-5.44%
Win Rate
34%17 out of 50
Risk vs Reward
Poor
Good
Matthew Biegler's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Fate Therapeutics IncFATE | +222.98% | $24.80 | $80.10 | 2020-04-05 - 2021-04-06 | Buy |
Oric Pharmaceuticals IncORIC | +202.61% | $4.99 | $15.10 | 2023-03-15 - 2024-03-15 | Buy |
Aptose Biosciences IncAPTO | +189.86% | $31.05 | $90.00 | 2019-01-24 - 2020-01-24 | Buy |
Ideaya Biosciences IncIDYA | +138.55% | $10.74 | $25.62 | 2022-08-15 - 2023-08-15 | Buy |
Turning Point Therapeutics IncTPTX | +111.67% | $35.91 | $76.01 | 2022-01-20 - 2022-08-16 | Buy |
Matthew Biegler Analyst Color
Get additional color on Matthew Biegler's coverage of popular stocks
Matthew Biegler's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Vor Biopharma IncVOR | 5 | Buy | $15.00 | +782.35% | Reiterates | a month ago |
Alpine Immune Sciences IncALPN | 1 | Buy | $44.00 | -31.91% | Reiterates | a month ago |
Oric Pharmaceuticals IncORIC | 2 | Buy | $17.00 | +121.64% | Maintains | a month ago |
Olema Pharmaceuticals IncOLMA | 3 | Buy | $21.00 | +113.63% | Reiterates | 2 months ago |
Arvinas IncARVN | 1 | Buy | $80.00 | +153.16% | Reiterates | 2 months ago |
Blueprint Medicines CorpBPMC | 4 | Buy | $85.00 | -6.32% | Upgrades | 6 months ago |
Fulcrum Therapeutics IncFULC | 4 | Buy | $16.00 | +124.40% | Reiterates | 8 months ago |
Medicenna Therapeutics CorpMDNAF | 3 | Buy | $3.00 | +1,810.83% | Maintains | 8 months ago |
Aptose Biosciences IncAPTO | 5 | Buy | $15.00 | +1,193.10% | Maintains | 9 months ago |
Ideaya Biosciences IncIDYA | 2 | Buy | $35.00 | -9.37% | Maintains | 9 months ago |
Relay Therapeutics IncRLAY | 3 | Buy | $33.00 | +436.15% | Reiterates | 9 months ago |
Ambrx Biopharma IncAMAM | 1 | Buy | $30.00 | +7.14% | Initiates Coverage On | a year ago |
Acrivon Therapeutics IncACRV | 1 | Buy | $25.00 | +195.16% | Initiates Coverage On | a year ago |
Zentalis Pharmaceuticals IncZNTL | 5 | Buy | $50.00 | +355.17% | Reiterates | a year ago |
Tyra Biosciences IncTYRA | 2 | Buy | $25.00 | +65.45% | Reiterates | a year ago |
Portage Biotech IncPRTG | 1 | Buy | $18.00 | N/A | Maintains | a year ago |
Nkarta IncNKTX | 2 | Buy | $36.00 | N/A | Maintains | a year ago |
Celularity IncCELU | 1 | Buy | $90.00 | N/A | Initiates Coverage On | 2 years ago |
Turning Point Therapeutics IncTPTX | 3 | Buy | $105.00 | N/A | Maintains | 2 years ago |
Fate Therapeutics IncFATE | 1 | Buy | $34.00 | N/A | Maintains | 4 years ago |
Q32 Bio IncQTTB | 1 | Buy | $576.00 | N/A | Upgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.